Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570675 | 0.92 | SMN1; SMN2 (0.36) | L3MBTL1TDP1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL17209724 | 0.88 | L3MBTL1 (0.40) | L3MBTL1SMN1; SMN2ALDH1A1NPC1GAA | |
| SCHEMBL17112312 | 0.85 | ALDH1A1 (0.39) | L3MBTL1SMN1; SMN2ALDH1A1NPC1NAMPT | |
| SCHEMBL28730480 | 0.84 | L3MBTL1 (0.33) | L3MBTL1SMN1; SMN2ALDH1A1NPC1GAA | |
| SCHEMBL12031906 | 0.82 | L3MBTL1 (0.33) | L3MBTL1TDP1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6094890 | 0.79 | SMN1; SMN2 (0.36) | TDP1SMN1; SMN2ALDH1A1NPC1GAA | |
| SCHEMBL17760913 | 0.77 | IDE (0.39) | SMN1; SMN2NPC1NAMPTLMNACYP19A1 | |
| SCHEMBL19125727 | 0.77 | EPHX1 (0.40) | L3MBTL1SMN1; SMN2ALDH1A1GAALMNA | |
| SCHEMBL4256419 | 0.76 | QPCT (0.43) | L3MBTL1TDP1SMN1; SMN2GAAHTT | |
| SCHEMBL13519414 | 0.75 | TBXAS1 (0.53) | TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3778622-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3218392-B1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633419-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | L3MBTL1 1391/4885TDP1 1967/4885SMN1; SMN2 4268/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | L3MBTL1 1391/4885TDP1 1967/4885SMN1; SMN2 4268/4885 |
| US-10633419-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | L3MBTL1 1391/4885TDP1 1967/4885SMN1; SMN2 4268/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | L3MBTL1 1391/4885TDP1 1967/4885SMN1; SMN2 4268/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | L3MBTL1 1391/4885TDP1 1967/4885SMN1; SMN2 4268/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | L3MBTL1 1391/4885TDP1 1967/4885SMN1; SMN2 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.